Skip to main content
Sinocelltech Group Limited logo

Sinocelltech Group Limited — Investor Relations & Filings

Ticker · 688520 ISIN · CNE100003ZL3 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 659 across all filing types
Latest filing 2022-11-07 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688520

About Sinocelltech Group Limited

https://www.sinocelltech.com/

Sinocelltech Group Limited focuses on the research, development, and commercialization of innovative biologics, including monoclonal antibodies, recombinant proteins, and vaccine candidates. The company's product pipeline addresses therapeutic areas such as oncology, autoimmune disorders, hematology, and infectious diseases. Key offerings include recombinant human coagulation factor VIII for hemophilia A and a range of biosimilars. Sinocelltech leverages an integrated technology platform encompassing early-stage discovery through to large-scale industrial production. This infrastructure supports the development of high-quality biological medicines aimed at addressing unmet medical needs through advanced protein engineering and cell line development.

Recent filings

Filing Released Lang Actions
北京神州细胞生物技术集团股份公司向特定对象发行人民币普通股认购资金到账情况验资报告
Audit Report / Information Classification · 95% confidence The document is an audit verification report issued by PwC (普华永道) regarding the receipt of subscription funds for a specific issuance of RMB ordinary shares by Beijing Shenzhou Cell Biotechnology Group Co., Ltd. It includes details about the share issuance, approval by the China Securities Regulatory Commission, and confirmation of funds received in a designated bank account. The document is titled as a "验资报告" (Capital Verification Report) and is signed by the accounting firm. It is not a full annual or interim financial report but a standalone audit verification related to a capital raising event. Therefore, it fits the category of an Audit Report / Information (AR) rather than a Capital/Financing Update (CAP) or Regulatory Filing (RNS). The document length is sufficient and contains substantive audit content, not merely an announcement or certification. Hence, the classification is AR with high confidence. FY 2022
2022-11-07 Chinese
关于北京神州细胞生物技术集团股份公司2021年度向特定对象发行A股股票发行过程和认购对象合规性的报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report from multiple securities firms regarding the compliance and process of a specific issuance of A shares by Beijing Shenzhou Cell Biotechnology Group Co., Ltd. in 2021. It includes extensive information about the issuance price, number of shares, investors, regulatory approvals, board and shareholder meeting approvals, subscription process, investor suitability checks, and capital verification by an accounting firm. The document references regulatory approvals from the China Securities Regulatory Commission and Shanghai Stock Exchange, and it is a comprehensive compliance and process report related to a capital raising event. This fits the definition of a Capital/Financing Update (CAP), as it provides detailed updates on the company's fundraising and issuance process rather than being a full annual report, audit report, or other types of filings. The document length and detail confirm it is not a mere announcement or certification but a substantive report on the capital issuance process and compliance.
2022-11-07 Chinese
北京市金杜律师事务所关于北京神州细胞生物技术集团股份公司2021年度向特定对象发行股票发行过程和认购对象合规性的法律意见书
Capital/Financing Update Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2021 private placement (向特定对象发行股票) of A shares by Beijing Shenzhou Cell Technology Group Co., Ltd. It details the approval and authorization process, the issuance process, subscription objects, pricing, allotment, payment, and compliance of the subscribers. The document references specific regulatory frameworks such as the Securities Law of the People's Republic of China, the China Securities Regulatory Commission (CSRC) registration approval, and Shanghai Stock Exchange review. It is a detailed legal opinion on the issuance process and compliance of the private placement, not a financial report, earnings release, or general regulatory filing. It is not a report publication announcement since it contains substantive legal analysis and detailed issuance information. The document is not a proxy statement, board/management change, or audit report. It is a legal opinion letter related to capital raising through a private placement, which fits best under Capital/Financing Update (CAP). The document length (11681 characters) and content confirm it is a full legal opinion on the capital raising event, not a brief announcement or certification. Therefore, the classification is CAP with high confidence.
2022-11-07 Chinese
北京神州细胞生物技术集团股份公司向特定对象发行人民币普通股验资报告
Audit Report / Information Classification · 95% confidence The document is a detailed verification report issued by PwC (普华永道) regarding the capital increase of Beijing Shenzhou Cell Biotechnology Group Co., Ltd. through a private placement of RMB ordinary shares. It includes audit opinions on the capital raised, detailed financial figures about the share issuance, approval documents from the China Securities Regulatory Commission, and attachments such as capital increase details and capital structure changes. The document is titled as a "验资报告" (Capital Verification Report) and contains substantive financial data and audit results related to the issuance of shares and capital increase. This is not a simple announcement or a certification letter but a full audit verification report on the capital raised through a specific financing activity. Therefore, it fits best under the category of Audit Report / Information (AR), which covers standalone audit reports and applied accounting principles related to capital raising and verification, excluding full annual reports. The document length (over 10,000 characters) and detailed financial data confirm it is a full report, not just an announcement or certification. FY 2022
2022-11-07 Chinese
神州细胞2022年第三季度报告
Interim / Quarterly Report Classification · 98% confidence The document is titled '2022 年第三季度报告' which translates to '2022 Third Quarter Report'. It contains detailed financial data including income statement, balance sheet, cash flow statement, and notes for the third quarter period ending September 30, 2022. The document explicitly states it is unaudited and covers the quarterly financial performance and key financial indicators. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements and substantive financial data. The document is not a brief announcement or a certification letter, and it is longer than 5,000 characters, so it is not a report publication announcement or regulatory filing. Therefore, the correct classification is IR with high confidence. 9M 2022
2022-10-27 Chinese
神州细胞2022年前三季度业绩预增的自愿性披露公告
Earnings Release Classification · 95% confidence The document is a voluntary earnings forecast announcement for the first three quarters of 2022 by Beijing Shenzhou Cell Biotechnology Group Co., Ltd. It provides preliminary estimated financial results such as revenue and net loss for the period January 1 to September 30, 2022, and compares them to the prior year. The document explicitly states that the final accurate financial data will be disclosed in the official 2022 third quarter report. The document length is short (1014 characters) and it does not contain detailed financial statements or substantive financial data, only preliminary estimates and a risk warning. This matches the characteristics of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only, rather than a full Interim/Quarterly Report (IR) which would contain detailed financial statements and analysis. Therefore, the correct classification is Earnings Release (ER). 9M 2022
2022-10-23 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.